Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

AIM: The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and ≤48 h anticoagulation prior to randomization undergoing cardioversion. METHODS: One thousand five hundred patients were randomized. The apixaban dose of 5 mg b.i.d....

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur Heart J
Prif Awduron: Ezekowitz, Michael D, Pollack, Charles V, Halperin, Jonathan L, England, Richard D, VanPelt Nguyen, Sandra, Spahr, Judith, Sudworth, Maria, Cater, Nilo B, Breazna, Andrei, Oldgren, Jonas, Kirchhof, Paulus
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2018
Pynciau:
Fast Track Clinical Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6110194/
https://ncbi.nlm.nih.gov/pubmed/29659797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehy148
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg